{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:51:15Z","timestamp":1770479475946,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":3817,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.jpainsymman.2008.08.005","type":"journal-article","created":{"date-parts":[[2009,4,13]],"date-time":"2009-04-13T04:10:43Z","timestamp":1239595843000},"page":"244-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Switching Breast Cancer Patients with Progressive Bone Metastases to Third-Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone Pain"],"prefix":"10.1016","volume":"38","author":[{"given":"Reuben","family":"Broom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Eton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dranitsaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2008.08.005_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00001813-199210000-00002","article-title":"Bone metastasis in breast cancer","volume":"3","author":"Theriault","year":"1992","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02405012","article-title":"Structure-activity relationships of various bisphosphonates","volume":"35","author":"Shinoda","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib4","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/106002809202601015","article-title":"Pamidronate","volume":"26","author":"Kellihan","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib6","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib10","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9583-y","article-title":"A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy","volume":"108","author":"Clemons","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","article-title":"Validation of the Brief Pain Inventory for chronic nonmalignant pain","volume":"5","author":"Tan","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/0959-8049(92)90510-9","article-title":"Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?","volume":"28","author":"Verger","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","article-title":"Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life","volume":"52","author":"Wyrwich","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpainsymman.2008.08.005_bib16","series-title":"Statistical power analysis for the behavioral science","author":"Cohen","year":"1988"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392409000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392409000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:01:35Z","timestamp":1760130095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392409000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0885392409000657"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.08.005","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching Breast Cancer Patients with Progressive Bone Metastases to Third-Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone Pain","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}